• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

    11/25/24 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CUE alert in real time by email

    BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, announced today that it will take part in an unplugged fireside discussion at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY, Dec 3-5, 2024.

    During the fireside discussion, Cue Biopharma will provide an overview highlighting recent clinical and preclinical program updates as well as strategic business and partnering model objectives.

    Presentation Details

    Date and Time: Wednesday, December 4, 2024, from 9 a.m. EST – 9:25 a.m. EST

    Webcast Link: https://event.webcasts.com/starthere.jsp?ei=1697351&tp_key=a82c532edc

    Presenter: Daniel Passeri, M.Sc., J.D., chief executive officer, Cue Biopharma

    A live and archived webcast of the fireside discussion will be available on the Events page in the Investors and Media section of the Company's website at www.cuebiopharma.com. The webcast will be archived for 30 days.

    About Cue Biopharma

    Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body. The company's proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.

    Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

    For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn.

    Investor Contact

    Marie Campinell 

    Senior Director, Corporate Communications

    Cue Biopharma, Inc.

    [email protected]

    Media Contact

    Jonathan Pappas

    LifeSci Communications

    [email protected]



    Primary Logo

    Get the next $CUE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What is the main focus of Cue Biopharma?

      Cue Biopharma is a clinical-stage biopharmaceutical company focusing on developing injectable biologics to modulate disease-specific T cells, targeting cancer and autoimmune diseases.

    • When and where will the Piper Sandler Healthcare Conference take place?

      The Piper Sandler 36th Annual Healthcare Conference will be held from December 3 to December 5, 2024, in New York, NY.

    • Who will be presenting at the fireside discussion and when is it scheduled?

      Daniel Passeri, the CEO of Cue Biopharma, will present during the fireside discussion on December 4, 2024, from 9 a.m. to 9:25 a.m. EST.

    • Will the presentation be available online and how long will it be accessible?

      The webcast of the fireside discussion will be available live and archived for 30 days on Cue Biopharma's website.

    • What topics will Cue Biopharma cover in their upcoming presentation at the conference?

      Cue Biopharma aims to provide updates on recent clinical and preclinical programs, as well as strategic business and partnering models during the discussion.

    Recent Analyst Ratings for
    $CUE

    DatePrice TargetRatingAnalyst
    3/13/2024$6.00Buy
    Jefferies
    6/26/2023$10.00Outperform
    Oppenheimer
    11/21/2022$7.00Overweight
    Piper Sandler
    1/13/2022$20.00Buy
    H.C. Wainwright
    1/3/2022$28.00Buy
    Craig Hallum
    More analyst ratings

    $CUE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Singapore-based ImmunoScape Pioneers Next-Generation Cell Therapy for Solid Tumors; Announces Key Licensing Deal, New Board and SAB Appointments

    "Seed-and-Boost" Approach with Breakthrough Potential, Poised to Transform the Cancer Immunotherapy Landscape ImmunoScape Pte. Ltd., an A*STAR spin out backed by Amgen Ventures and EDBi that is developing next-generation TCR-based cancer immunotherapies, today announced an exclusive in-licensing deal with Cue Biopharma Inc. (NASDAQ:CUE) to lead the development of a distinct new class of therapies to attack solid tumor cancers. The deal provides ImmunoScape with exclusive access to Cue Biopharma's clinical-stage Immuno-STAT® molecules in oncology. By combining Cue Biopharma's technology with its precision T cell receptor (TCR) therapy, ImmunoScape is pioneering a new "Seed-and-Boost" app

    11/13/25 1:10:00 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

    Announced strategic collaboration and license agreement with ImmunoScape to develop breakthrough cell therapy approach for solid tumors – Company is entitled to receive upfront payments totaling $15M Announced strategic transition in leadership to further enable next stage of growth with disruptive autoimmune therapeutic candidates, most notably CUE-401, the Company's lead autoimmune asset BOSTON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today provided a busine

    11/12/25 4:05:00 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors

    Exclusive collaboration and license agreement focuses on advancing novel T cell therapy "Seed-and-Boost" approach exploiting the mechanism of the CUE-100 series of Immuno-STATs®Novel therapeutic approach is designed to enable in vivo expansion and activation of infused T cell receptor engineered T cells (TCR-Ts) to provide durability, tolerability and enhanced clinical benefit while reducing manufacturing complexityCompelling data generated in preclinical models of multiple solid tumors, including pancreatic and ovarian, demonstrates the clinical potential of this novel immunotherapy approach with IND-enabling studies on track for 2027 submission BOSTON and SINGAPORE, Nov. 06, 2025 (GLOBE

    11/6/25 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    SEC Filings

    View All

    Cue Biopharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cue Biopharma, Inc. (0001645460) (Filer)

    11/24/25 8:08:12 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma Inc. filed SEC Form 8-K: Leadership Update

    8-K - Cue Biopharma, Inc. (0001645460) (Filer)

    11/20/25 4:00:24 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Cue Biopharma Inc.

    10-Q - Cue Biopharma, Inc. (0001645460) (Filer)

    11/12/25 4:01:00 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by SVP, GENERAL COUNSEL Sandercock Colin

    4 - Cue Biopharma, Inc. (0001645460) (Issuer)

    12/5/25 6:54:26 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CHIEF DEVELOPMENT OFFICER Baker Daniel G.

    4 - Cue Biopharma, Inc. (0001645460) (Issuer)

    11/25/25 4:00:04 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CHIEF BUSINESS OFFICER Warren Lucinda

    4 - Cue Biopharma, Inc. (0001645460) (Issuer)

    11/25/25 4:00:05 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Cue Biopharma with a new price target

    Jefferies initiated coverage of Cue Biopharma with a rating of Buy and set a new price target of $6.00

    3/13/24 7:30:48 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer resumed coverage on Cue Biopharma with a new price target

    Oppenheimer resumed coverage of Cue Biopharma with a rating of Outperform and set a new price target of $10.00

    6/26/23 7:24:09 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Cue Biopharma with a new price target

    Piper Sandler initiated coverage of Cue Biopharma with a rating of Overweight and set a new price target of $7.00

    11/21/22 7:39:31 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Passeri Daniel R bought $30,900 worth of shares (30,000 units at $1.03), increasing direct ownership by 22% to 164,578 units (SEC Form 4)

    4 - Cue Biopharma, Inc. (0001645460) (Issuer)

    12/18/24 4:00:04 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    Leadership Updates

    Live Leadership Updates

    View All

    Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

    BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the appointment of industry veteran Lucinda Warren as chief business officer (CBO). With an extensive background and proven expertise in strategic transactions, portfolio optimization and alliance management through her extensive tenure at Johnson & Johnson and Jansen, Ms. Warren will play a pivotal role in advancing Cue Biopharma's core corporate objectives following the company's recent business restructuring and autoimmune program prioritizati

    9/9/24 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors

    BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today the appointment of seasoned pharmaceutical executive Pamela D. Garzone, Ph.D., to its board of directors. Dr. Garzone brings to Cue Biopharma more than 25 years of healthcare and pharmaceutical industry experience in drug development, including strategic, scientific, clinical and regulatory leadership expertise. "We are pleased to have Dr. Garzone join our board of directors," said Daniel Passeri, chief executive

    4/25/23 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors

    BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today the appointment of industry veteran Patrick Verheyen to its board of directors (BOD). Mr. Verheyen brings to Cue Biopharma more than 35-years of experience facilitating pipeline growth and innovation programs at Janssen Pharmaceutical Companies of Johnson and Johnson. "We are very pleased to welcome Mr. Verheyen to our BOD and leverage his extensive experience and guidance as we seek to enhance and broaden Cue Bi

    4/12/23 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cue Biopharma Inc.

    SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)

    3/11/24 6:40:41 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cue Biopharma Inc.

    SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)

    2/7/24 5:09:04 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cue Biopharma Inc.

    SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)

    1/31/24 2:08:28 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    Financials

    Live finance-specific insights

    View All

    Cue Biopharma to Host Business Update Call and Webcast

    BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that it will host a conference call and webcast to provide a business update on Tuesday, April 15, 2025 at 4:30 p.m. ET. Conference Call and Webcast DetailsTuesday, April 15 at 4:30 p.m. ET Investors:1-844-826-3035International Investors:1-412-317-5195Conference ID:10199037Webcast Link:https://viavid.webcasts.com/starthere.jsp?ei=1715808&tp_key=9378826572 The live and archived webcast will also b

    4/14/25 5:02:00 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma to Host Business Update Call and Webcast

    BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, August 19, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website. The company will provide a business overview of its recent restructuring and near-term strategic prioritization objectives. The discussion will focus on the company's approach to enhance near-term shareholder value by refocusing resourc

    8/13/24 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma to Host Business Update Call and Webcast

    BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, April 8, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website. The Company will provide a corporate update highlighting measurable progress advancing its lead clinical oncology programs, CUE-101 and CUE-102, its lead preclinical autoimmune program CUE-401 partnered with Ono Pharmaceutical, as well as additional au

    4/2/24 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care